Causaly alternative · for oncology biotech medical affairs
Causaly alternative for oncology medical affairs: oncology depth, mid-market pricing
UNMIRI · See Literature Intelligence
Causaly built a great R&D platform. In September 2025 they launched Causaly Agentic Research, a multi-agent system aimed squarely at target identification, biomarker discovery, and competitive intelligence for research scientists at large pharma. Causaly's enterprise pricing is not publicly disclosed, but is generally understood to sit in the mid-six-figure-and-up ACV band typical of biopharma R&D platforms, with a 6–9 month procurement cycle sold to the CMO and head of medical affairs.
For a 50-500 person oncology biotech medical affairs team with two drugs, six MSLs, and a quarterly competitive readout to ship, the math gets hard fast. UNMIRI Engine 3 is live today and oncology-only by design: citation-grounded summaries an MLR reviewer can defend, $149/month individual or $599/month team self-serve, no procurement cycle to get started. It fits a lean biotech team, and it also gives an oncology medical affairs group inside a larger pharma a way to evaluate oncology-specific depth without a top-down enterprise purchase. Pick what fits your team.
At a glance
| Dimension | Causaly | UNMIRI |
|---|---|---|
| Primary scope | All of biology: target ID, biomarker discovery, R&D | Oncology-only, surveillance + KOL + competitive landscape |
| Pricing entry | Mid-six-figure+ enterprise ACV (not publicly disclosed) | $149/mo individual, $599/mo team, enterprise custom (unlimited, SSO, BAA) |
| Buyer profile | Top-20 pharma R&D + large biopharma research scientists | Oncology medical affairs teams: lean biotech, or an oncology group inside a larger pharma |
| Procurement cycle | Sales-led, 6-9 month procurement, MSA negotiation | PLG: trial Tuesday, no credit card, 14-day evaluation |
| Reasoning approach | Multi-agent research with evidence matrix | Deterministic templates over a variant-aware oncology graph; LLMs scoped to extraction edges only |
| KOL graph | Cross-domain biomedical, all therapeutic areas | Oncology-only, variant-stratified (KOLs ranked by EGFR L858R or KRAS G12C separately) |
| Output | Causaly UI + integrations | Daily/weekly digest, KOL profiles, competitive landscape PDF, watchlist alerts, FHIR / API |
Same goal, different mechanism
Both products share the citation-grounded principle, which is the right architecture for pharma-defensible MLR-ready output. Where they differ is mechanism: Causaly leans into multi-agent reasoning with evidence matrices showing the chain of inference. UNMIRI uses deterministic templates rendered from extracted graph fields (no LLM free-writing produces any prose claim) with reproducibility snapshots so a digest from May 12 can be regenerated identically months later.
For R&D scientists exploring open hypotheses, Causaly's agentic approach is the right tool. For medical affairs work that has to survive medical, legal, and regulatory review, the deterministic-template approach is easier to defend and easier to audit. Different mechanism, different fit.
When Causaly is the right pick
- You're top-20 pharma running multi-therapeutic-area R&D with established enterprise procurement.
- Your work spans all of biology and you actually use the cross-domain coverage.
- You need agentic research workflows for hypothesis generation across thousands of papers.
- Sales-led, six-figure procurement is your default buying motion and your IT team is set up for it.
When UNMIRI is the right pick
- Your oncology medical affairs team is six to twenty people, whether at a lean biotech or as an oncology group inside a larger pharma.
- Your therapeutic-area + competitive-set filter is narrow: oncology, your drug + four to six competitors.
- You want to start the trial today, not negotiate it for two quarters.
- Variant-aware reasoning matters: KOLs publishing on EGFR L858R are different from those on EGFR exon 20 insertions, and the system needs to know the difference.
- Your medical leadership reviews every claim in every digest. Deterministic-template output is easier to defend in MLR than a multi-agent reasoning trace.
Frequently asked questions
- Can we evaluate UNMIRI without buying out of Causaly?
- Yes. Individual or Team tier is no-friction to set up. Many teams run parallel evaluation against an existing Causaly subscription before deciding which tool fits which workflow. There is no exclusivity in UNMIRI's terms.
- How long does the free trial last?
- 14 days, no credit card required (the trial is capped at 25 AI queries). The Engine 3 product surface (signup → dashboard → Ask → variant search → watchlists → KOL profiles → med-info CRM) is live now at app.unmiri.com/m/signup.
- What about enterprise pricing?
- Enterprise is custom: unlimited AI queries, SSO, a BAA on the Enterprise tier, and Salesforce integration (Veeva on request). Educational and advocacy non-profits get a discounted band. The published self-serve tiers are $149/mo individual and $599/mo team; we don't quote six-figure ACVs at the entry, which is the design.
- Is the variant-aware reasoning really different from Causaly?
- Yes. Variant-level relevance scoring and KOL ranking both incorporate variant signal from the same Neo4j knowledge graph that powers UNMIRI's Engine 1 and Engine 2. KOLs publishing on EGFR L858R are ranked separately from KOLs publishing on EGFR exon 20 insertions, and the digest filter respects that distinction.
- Why not multi-agent / LLM reasoning?
- Multi-agent reasoning is powerful for open-ended R&D exploration. For medical affairs work that has to survive MLR review, deterministic templates rendered from extracted graph fields are easier to defend, easier to reproduce, and easier to audit one year later. We use LLMs narrowly for extraction edge cases only, never for prose claims.
See how it compares for your workflow
Spin up a 14-day trial against your therapeutic-area + competitive-set filter. No credit card. If it doesn't fit, you delete the account and we don't chase you.